Tradestie Institutional Equity Comparison Engine
BHVN vs NTLA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BHVN Overall Edge
BHVN Captures Institutional Edge (3โ0 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biohaven Ltd. (BHVN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BHVN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus NTLA at N/M Forward P/E and -826.0% operating margin (-48.0% YoY). In options structure, BHVN sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro) against NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
BHVN N/M vs NTLA N/M Fwd P/E
Growth & Margin Winner
BHVN
Op Margin 0.0% vs -826.0% ยท YoY +0.0% vs -48.0%
Momentum & Technical Winner
BHVN
1Y +72.1% vs +15.3% ยท 52W Pos 59% vs 20%
Options & Structure Winner
BHVN
CONSOLIDATION (18th %ile IV) vs BREAKDOWN (78th %ile IV)
BHVN
NYSE
Biohaven Ltd.
Pharmaceutical Preparations
$13.90
+0.62% 1D
Market Cap
$2.1B
1M Return
+28.99%
1Y Return
+72.09%
Forward P/E
N/M
Unified AI Score
42.1 / 100
HOLD
Tech 15.0
Fund 42.0
Flow 68.0
Mom 50.0
NTLA
NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap
$1.5B
1M Return
-12.43%
1Y Return
+15.34%
Forward P/E
N/M
Unified AI Score
50.7 / 100
HOLD
Tech 47.0
Fund 55.0
Flow 59.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BHVN +72.09%
NTLA +15.34%
Spread: +56.75 pp (BHVN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BHVN TTM Op. Margin: 0.0%
NTLA TTM Op. Margin: -826.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHVN vs NTLA. Trailing 12-month operating profitability (BHVN 0.0% vs NTLA -826.0%) and valuation multiples (BHVN N/M vs NTLA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BHVN | NTLA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $1.5B | Larger Scale | BHVN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -48.0% | Higher Growth | BHVN |
| Operating Margin (TTM) Profitability | 0.0% | -826.0% | Higher Margin | BHVN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -799.5% | -62.6% | Higher ROE | NTLA |
| 52-Week Range Position Momentum | 59% ($8โ$18) | 20% ($8โ$18) | Stronger Trend | BHVN |
| Beta / 30D Volatility Risk Regime | 1.41ฮฒ ยท 111% Vol | 2.30ฮฒ ยท 87% Vol | Lower Realized Risk | NTLA |
| Unified Institutional Score Composite Signal | 42.1 / 100 (HOLD) | 50.7 / 100 (HOLD) | Higher Composite | NTLA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BHVN vs NTLA Buy Guide
BHVN
CONSOLIDATION
91d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
18th %ile
IV Regime
Compressed (<25th %ile)
NTLA
BREAKDOWN
94d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
78th %ile
IV Regime
Elevated (60thโ80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BHVN nor NTLA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.